Issues related to drug pricing, including federal proposals impacting reimbursement, access, and affordability; Issues related to Medicare Drug negotiation and implementation of the Inflation Reduction Act; Pharmacy benefit manager reform legislation; Issues related to Most Favored Nation (MFN) pricing models
2025 · 4th Quarter (Oct 1 - Dec 31)
BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.)
Filed by BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.).
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 21, 2026
- Income
- Not reported
- Expenses
- $230,000.00
- Filing UUID
- 99bcc3ec-7e5c-4fe0-8741-21e9ac9d2114
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Engaged with the Securities and Exchange Commission on a regulatory matter
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.